vs
Apellis Pharmaceuticals, Inc.（APLS）与PagerDuty, Inc.（PD）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是PagerDuty, Inc.的1.6倍（$199.9M vs $124.5M），PagerDuty, Inc.净利率更高（129.7% vs -29.5%，领先159.2%），PagerDuty, Inc.同比增速更快（4.7% vs -5.9%），PagerDuty, Inc.自由现金流更多（$24.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 5.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
PagerDuty是一家美国云计算企业，主打面向IT运维部门的SaaS事件管理平台，可帮助企业实时响应运维异常、快速定位并处理故障，保障业务系统稳定运行，目前已成为全球IT运维领域广受认可的数字化解决方案服务商。
APLS vs PD — 直观对比
营收规模更大
APLS
是对方的1.6倍
$124.5M
营收增速更快
PD
高出10.6%
-5.9%
净利率更高
PD
高出159.2%
-29.5%
自由现金流更多
PD
多$38.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
5.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $124.5M |
| 净利润 | $-59.0M | $161.6M |
| 毛利率 | — | 85.3% |
| 营业利润率 | -25.6% | 6.5% |
| 净利率 | -29.5% | 129.7% |
| 营收同比 | -5.9% | 4.7% |
| 净利润同比 | -62.2% | 2827.7% |
| 每股收益（稀释后） | $-0.40 | $1.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPD
| Q4 25 | $199.9M | $124.5M | ||
| Q3 25 | $458.6M | $123.4M | ||
| Q2 25 | $178.5M | $119.8M | ||
| Q1 25 | $166.8M | $121.4M | ||
| Q4 24 | $212.5M | $118.9M | ||
| Q3 24 | $196.8M | $115.9M | ||
| Q2 24 | $199.7M | $111.2M | ||
| Q1 24 | $172.3M | $111.1M |
净利润APLSPD
| Q4 25 | $-59.0M | $161.6M | ||
| Q3 25 | $215.7M | $9.6M | ||
| Q2 25 | $-42.2M | $-7.2M | ||
| Q1 25 | $-92.2M | $-8.8M | ||
| Q4 24 | $-36.4M | $-5.9M | ||
| Q3 24 | $-57.4M | $-10.9M | ||
| Q2 24 | $-37.7M | $-17.1M | ||
| Q1 24 | $-66.4M | $-28.2M |
毛利率APLSPD
| Q4 25 | — | 85.3% | ||
| Q3 25 | — | 84.6% | ||
| Q2 25 | — | 84.0% | ||
| Q1 25 | — | 83.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | — | 82.7% | ||
| Q2 24 | — | 82.6% | ||
| Q1 24 | — | 81.7% |
营业利润率APLSPD
| Q4 25 | -25.6% | 6.5% | ||
| Q3 25 | 48.7% | 2.9% | ||
| Q2 25 | -18.6% | -8.6% | ||
| Q1 25 | -50.0% | -9.6% | ||
| Q4 24 | -12.3% | -8.7% | ||
| Q3 24 | -24.0% | -13.8% | ||
| Q2 24 | -14.7% | -19.5% | ||
| Q1 24 | -36.0% | -30.1% |
净利率APLSPD
| Q4 25 | -29.5% | 129.7% | ||
| Q3 25 | 47.0% | 7.8% | ||
| Q2 25 | -23.6% | -6.0% | ||
| Q1 25 | -55.3% | -7.2% | ||
| Q4 24 | -17.1% | -5.0% | ||
| Q3 24 | -29.2% | -9.4% | ||
| Q2 24 | -18.9% | -15.4% | ||
| Q1 24 | -38.5% | -25.3% |
每股收益（稀释后）APLSPD
| Q4 25 | $-0.40 | $1.69 | ||
| Q3 25 | $1.67 | $0.10 | ||
| Q2 25 | $-0.33 | $-0.07 | ||
| Q1 25 | $-0.74 | $-0.12 | ||
| Q4 24 | $-0.30 | $-0.07 | ||
| Q3 24 | $-0.46 | $-0.14 | ||
| Q2 24 | $-0.30 | $-0.26 | ||
| Q1 24 | $-0.54 | $-0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $547.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $320.5M |
| 总资产 | $1.1B | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPD
| Q4 25 | $466.2M | $547.8M | ||
| Q3 25 | $479.2M | $567.9M | ||
| Q2 25 | $370.0M | $597.1M | ||
| Q1 25 | $358.4M | $570.8M | ||
| Q4 24 | $411.3M | $542.2M | ||
| Q3 24 | $396.9M | $599.3M | ||
| Q2 24 | $360.1M | $592.8M | ||
| Q1 24 | $325.9M | $571.2M |
总债务APLSPD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | $489.5M |
股东权益APLSPD
| Q4 25 | $370.1M | $320.5M | ||
| Q3 25 | $401.2M | $180.7M | ||
| Q2 25 | $156.3M | $145.7M | ||
| Q1 25 | $164.2M | $129.8M | ||
| Q4 24 | $228.5M | $111.6M | ||
| Q3 24 | $237.1M | $164.7M | ||
| Q2 24 | $264.3M | $174.0M | ||
| Q1 24 | $266.7M | $171.6M |
总资产APLSPD
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.1B | $891.5M | ||
| Q2 25 | $821.4M | $926.8M | ||
| Q1 25 | $807.3M | $927.3M | ||
| Q4 24 | $885.1M | $866.8M | ||
| Q3 24 | $901.9M | $916.0M | ||
| Q2 24 | $904.5M | $924.0M | ||
| Q1 24 | $831.9M | $925.3M |
负债/权益比APLSPD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | 2.85× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $24.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $24.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 19.3% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 0.15× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $117.6M |
8季度趋势，按日历期对齐
经营现金流APLSPD
| Q4 25 | $-14.2M | $24.8M | ||
| Q3 25 | $108.5M | $34.0M | ||
| Q2 25 | $4.4M | $30.7M | ||
| Q1 25 | $-53.4M | $31.4M | ||
| Q4 24 | $19.4M | $22.1M | ||
| Q3 24 | $34.1M | $35.8M | ||
| Q2 24 | $-8.3M | $28.6M | ||
| Q1 24 | $-133.0M | $22.2M |
自由现金流APLSPD
| Q4 25 | $-14.3M | $24.1M | ||
| Q3 25 | $108.3M | $33.1M | ||
| Q2 25 | $4.4M | $30.2M | ||
| Q1 25 | $-53.4M | $30.3M | ||
| Q4 24 | $19.3M | $21.5M | ||
| Q3 24 | — | $35.1M | ||
| Q2 24 | $-8.4M | $28.2M | ||
| Q1 24 | $-133.3M | $21.2M |
自由现金流率APLSPD
| Q4 25 | -7.1% | 19.3% | ||
| Q3 25 | 23.6% | 26.8% | ||
| Q2 25 | 2.5% | 25.2% | ||
| Q1 25 | -32.0% | 24.9% | ||
| Q4 24 | 9.1% | 18.1% | ||
| Q3 24 | — | 30.3% | ||
| Q2 24 | -4.2% | 25.4% | ||
| Q1 24 | -77.3% | 19.1% |
资本支出强度APLSPD
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.2% | 0.9% |
现金转化率APLSPD
| Q4 25 | — | 0.15× | ||
| Q3 25 | 0.50× | 3.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
